Therefore, the impact of eNAMPT signaling in triggering IFN-like responses in melanoma merits to be evaluated to investigate a potential NAMPT-dependent T cell and/or macrophage function modulation and response to immunotherapy, as well as the potential role of eNAMPT as prognostic and predictive biomarker of therapeutic response to ICIs. This evidence concerns the gene NAMPT and melanoma.